Publication:
Advances in the epigenetics of fibroblast biology and fibrotic diseases

Simple item page
dc.contributor.kuauthorUlukan, Bürge
dc.contributor.kuauthorÖzkaya, Yasemin Sıla
dc.contributor.kuauthorZeybel, Müjdat
dc.contributor.kuprofilePhD Student
dc.contributor.kuprofileUndergraduate Student
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteGraduate School of Health Sciences
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.contributor.yokid214694
dc.date.accessioned2024-11-09T23:25:32Z
dc.date.issued2019
dc.description.abstractFibroblasts have a central role in tissue fibrosis and fibrotic diseases. Fibroblast activation is regulated by several mechanisms including epigenetic modifications; histone modifications, DNA methylation and non-coding RNAs. Although research has significantly contributed to our basic understanding of fibrotic diseases over the last decade, cooperative activity of epigenetic mechanisms demonstrates the complexity of fibrogenesis. This review will summarise the latest epigenetic advances in fibroproliferative diseases. Current studies investigating biological implications of epigenetic modifiers, inhibitors of DNA methylation/histone modifying enzymes are promising. Given that ncRNA-based or CRISPR-based epigenetic-editing have shown therapeutic potential in the preclinical models; we consider epigenetic mechanisms represent a potential tool with clinical utility.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.sponsorshipScientific and Technological Research Council of Turkey [117S440, 218S245]
dc.description.sponsorshipRepublic of Turkey Ministry of Development This work is supported by The Scientific and Technological Research Council of Turkey 1001 grant [Grant number: 117S440, 2018] and Newton-Katip Celebi Fund 2551 [Grant number: 218S245, 2019]. The authors gratefully acknowledge use of the services and facilities of the Koc University Research Center for Translational Medicine (KUTTAM), funded by the Republic of Turkey Ministry of Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Ministry of Development.
dc.description.volume49
dc.identifier.doi10.1016/j.coph.2019.10.001
dc.identifier.eissn1471-4973
dc.identifier.issn1471-4892
dc.identifier.scopus2-s2.0-85074695407
dc.identifier.urihttp://dx.doi.org/10.1016/j.coph.2019.10.001
dc.identifier.urihttps://hdl.handle.net/20.500.14288/11380
dc.identifier.wos503086500010
dc.keywordsStellate cell activation
dc.keywordsDNA-methylation
dc.keywordsFibrosis progression
dc.keywordsPulmonary-fibrosis
dc.keywordsLiver-disease
dc.keywordsPromotes
dc.keywordsTransdifferentiation
dc.keywordsInhibition
dc.keywordsRasal1
dc.languageEnglish
dc.publisherElsevier Sci Ltd
dc.sourceCurrent Opinion In Pharmacology
dc.subjectPharmacology
dc.subjectPharmacy
dc.titleAdvances in the epigenetics of fibroblast biology and fibrotic diseases
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.authorid0000-0001-5440-4623
local.contributor.kuauthorUlukan, Bürge
local.contributor.kuauthorÖzkaya, Yasemin Sıla
local.contributor.kuauthorZeybel, Müjdat

Files

Collections

Publications without Fulltext